foxo4-dri senolytic peptide study inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis foxo4-dri senolytic peptide human trial

Anchor logic: why the two are stacked Think of tissue repair as a construction project with two independent bottlenecks

Vivani is developing an implantable GLP-1 product candidate designed for reversible 6-12 month dosing with steady PK that may also mitigate tolerability issues

Participants began with a starting dose of 0.25 mg per week for both cagrilintide and semaglutide, with the doses co-escalated every four weeks (to 0.5 mg, 1.0 mg, and 1.7 mg) until reaching the maintenance dose of 2.4 mg per week for each medication after 16 weeks

A history of cancer or active malignancy is frequently flagged in the literature as a reason for caution, because pathways involved in angiogenesis and cell migration are also relevant to tumor biology

What Our Happy Patients Are Saying 98% love their experience

Front Pharmacol 2021